New Study Suggests Duchenne Muscular Dystrophy’s Brain Impact May Be Reversible
A groundbreaking study led by scientists at the University of Portsmouth has revealed that Duchenne muscular dystrophy (DMD), a genetic condition long associated with severe muscle degeneration, also significantly affects the brain—causing diverse cognitive and behavioural symptoms that may, in part, be reversible.
Published in the journal Molecular Medicine, the research sheds new light on the broader impact of DMD, which affects approximately one in every 5,000 male births. While the disease is primarily known for progressive muscle wasting, the new findings show how it also disrupts brain development and metabolism, potentially contributing to learning difficulties, memory problems, and higher risks of ADHD and autism.
“For decades, we’ve focused on the muscles as their damage causes death of the patients. But the brain is also deeply affected by DMD,” said Professor Darek Gorecki, senior author of the study from the University’s School of Medicine, Pharmacy and Biological Sciences. “Understanding these changes is crucial to developing treatments that address the full scope of the disease—not just its muscle symptoms.”
The study found that the absence of full-length dystrophins—proteins crucial for muscle and brain function—leads to abnormalities in specific brain regions, including the hippocampus, cerebral cortex, amygdala, and cerebellum. Notably, these abnormalities change over time and vary by brain region.
“We now understand that these brain abnormalities develop differently in specific brain regions over time, meaning that targeted early intervention could be key,” said Professor Gorecki. “This discovery gives us real hope that we can improve at least some cognitive and behavioural symptoms in DMD patients.”
According to the research, patients with DMD tend to have IQs averaging one standard deviation below the general population, with around 30 percent scoring below 70. A particularly troubling finding was the role of a leaky blood-brain barrier, which allows inflammatory molecules from degenerating muscles to enter the brain—potentially worsening neurological symptoms.
The cerebellum, known for its role in motor control but also essential for language and cognitive development, was shown to be particularly vulnerable, maturing late and therefore more susceptible to changes postnatally.
Using advanced RNA sequencing and brain function analyses, the team—comprising 21 scientists from eight research institutions—identified that some brain abnormalities are already present at birth, while others emerge later in life.
“This means that we have a window of opportunity to intervene,” said Professor Gorecki. “By targeting these defects occurring after birth, we potentially could improve cognitive function in DMD patients.”
The research also highlights several promising therapeutic approaches. These include restoring dystrophin in the brain, using anti-inflammatory drugs to mitigate immune system overactivation, and even exploring dietary strategies such as the ketogenic diet to enhance brain performance.
“These findings give hope that we’re not just treating symptoms—we might actually be able to change the trajectory of the disease,” Professor Gorecki added.
The study not only expands scientific understanding of DMD but also paves the way for the development of targeted brain therapies that could significantly improve the quality of life for patients.
About the University of Portsmouth
The University of Portsmouth is a forward-thinking institution recognized globally for its excellence in teaching, research, and innovation. Rated 5 stars in the QS World University Rankings and among the UK’s top five young universities (Times Higher Education Young University Rankings), it continues to drive cutting-edge research that makes a tangible impact. Learn more at www.port.ac.uk